CROMSOURCE Acquires Pleiad: Expands US Coverage
CROMSOURCE, an international full service contract research organization (CRO) announced the acquisition of Pleiad, an international CRO with offices in the United States (Cambridge, Mass.) and United Kingdom (Stirling, Scotland).
Pleiad was launched in 1999, supporting clients in multiple therapy areas and with dedicated Medical Device and Ophthalmology Divisions. Additionally,Pleiad also encompasses particularly strong capabilities within statistics and data management.
"We are delighted to welcome Pleiad and its expert team," stated Dr Oriana Zerbini, Chief Executive Officer of CROMSOURCE. "For some time we have wanted to expand and consolidate our presence in the United States and we have now found the perfect way to do so. The opportunity to further add to our UK team and expand our team of experts in data management and statistics is also of great importance to us. With this collaboration CROMSOURCE reinforces its capability to support our clients with even the largest of development programmes in both Europe and the United States."
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
